In addition, SMYD2 promotes PTEN methylation at lysine 313 and reduces PTEN phosphorylation at serine 380, resulting in activation of the phosphatidylinositol 3-kinase-AKT pathway, thereby promoting BC cell growth17. Here, SMYD2 is linked to breast cancer.